Related Experiment Videos
Intravenous cisplatin for superficial bladder tumors
Cancer
|November 1, 1982
Summary
This study found that cisplatin chemotherapy was ineffective for treating low-stage bladder cancer, showing minimal tumor response and significant side effects like nausea and vomiting in patients.
Area of Science:
- Urology
- Medical Oncology
- Cancer Research
Background:
- Recurrent bladder tumors confined to the mucosa and lamina propria present a treatment challenge.
- Previous treatments like transurethral resection, irradiation, and thiophosphoramide were often insufficient.
Purpose of the Study:
- To evaluate the efficacy and safety of cisplatin in patients with recurrent, low-stage bladder tumors.
- To determine if cisplatin can control or eradicate superficial bladder carcinoma in situ.
Main Methods:
- Fifteen patients with recurrent flat carcinoma in situ and/or bladder tumors received intravenous cisplatin (1.25 mg/kg) every other day.
- Treatment response was assessed using urinary cytology, cystoscopy, and biopsy.
Main Results:
- Of 14 adequately treated patients, 28% showed temporary disappearance of visible lesions, with a median duration of 8 months.
- Six patients had a transient >50% reduction in tumor number, but none achieved complete remission.
- All patients maintained positive urinary cytology, and significant nausea and vomiting were reported.
Conclusions:
- Cisplatin, at the tested dose and schedule, demonstrated ineffectiveness in controlling low-stage bladder tumors.
- The observed side effects suggest a poor risk-benefit ratio for this treatment in this patient population.